They may turn up for annual review but it is unlikely they would ask: ‘How do I keep myself safe on a mountain top?’ Let’s just say, this patient turned up to his ‘well known’ London diabetes annual review and did not receive his doctor’s name (likely?!). Why did he not ask for it or remember it if given? I would like to suggest that he was not motivated to do so. He was ‘resistant’. Resistance and denial co-exist. They are employed by the mind to reduce the risk of stress via the avoidance of ‘problem

confrontation’. However, they are regarded as ineffective ways of dealing with problems and in health psychology lead to high risk health behaviours. This patient is clearly lucky to be alive. This Englishman is involved in high risk activities via

sport this website Selleckchem Pirfenidone and health care. Passively resistant and actively defiant cases have been outlined elsewhere.2,3 It is a form of pseudo freedom which many of our patients engage in. Strategies derived from learning theory will not help or change behaviour such as this as they do not consider unconscious drives in the process of decision making. A disease-focused psychotherapeutic approach may do more to keep risk takers safe (enough) than education and guidance. Then we can have all of the action and all of the content. “
“This chapter contains sections titled: Introduction Thresholds and targets for treatment Management Blood pressure measurement Pharmacological treatment: general features Preferred treatment: angiotensin blockade Angiotensin receptor blockers tuclazepam Calcium-channel blockers

Beta-blockers (British National Formulary, Section 2.4) Diuretics Other agents Resistant hypertension References Further reading “
“Peripheral arterial disease (PAD) affects around 14% of the population aged over 65 years. Patients with diabetes carry a two- to three-fold increased risk of PAD and have higher rates of complications, including gangrene and amputation. Intermittent claudication is a disabling symptom of PAD with limited effective therapeutic options. Cilostazol is a type 3 phosphodiesterase (PDE3) inhibitor licensed for use in intermittent claudication; it gained FDA approval in 1999. Cilostazol prevents the breakdown of cyclic adenosine monophosphate (cAMP) by inhibiting PDE3. (Figure 1.) Within vascular smooth muscle cAMP inhibits myosin light chain kinase, which is required for muscle contraction, and by increasing cAMP cilostazol promotes vasodilation. Within platelets cilostazol increases cAMP which inhibits platelet activation. The mechanism by which cilostazol improves walking distance is unclear. Cilostazol is taken orally at a usual dose of 100mg twice daily; it is metabolised in the liver and the active metabolites travel bound to protein, usually albumin, and are excreted predominantly in the urine.